Navigation Links
Breast Cancer Study Offers New Hope
Date:5/25/2010

Estrogen-lowering drugs before surgery let even high-risk women opt for lumpectomy

TUESDAY, May 25 (HealthDay News) --Giving certain breast cancer patients estrogen-lowering drugs before surgery enhances their chances of being able to choose a breast-conserving lumpectomy instead of a full mastectomy, new research suggests.

The observation was based on a national study launched at 118 hospitals across the United States. It focused on postmenopausal women who had been diagnosed with estrogen receptor-positive (ER+) breast cancer that was either at stage II or stage III -- that is, tumors that were around an inch or greater in size and might have spread to the lymph nodes under the arm.

The most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.

The 352 women who participated were monitored for tumor growth before and after being placed on a 16-week regimen of aromatase inhibitors -- estrogen-lowering agents -- before any surgery. Estrogen stimulates the growth of ER+ tumors.

The women were classified into three groups as the study began: "marginal", meaning that the women were eligible for a lumpectomy to conserve the breast, but that it would be disfiguring or require several operations; "mastectomy-only", meaning a lumpectomy was not considered possible; and "inoperable", meaning that doctors believed that even a mastectomy would not completely remove the cancer.

After the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.

More than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome. And 75 percent of those thought to be inoperable altogether were able to have breast-conservation surgery.

The investigation was funded by the American College of Surgeons Oncology Group and led by Dr. Julie A. Margenthaler, an assistant professor of surgery and a breast surgeon at the Siteman Cancer Center at Washington University in St. Louis.

"Aromatase inhibitor therapy shrank the tumors in many of these women and improved surgical outcomes," study chair Dr. Matthey J. Ellis, a breast cancer specialist at Washington University and Barnes-Jewish Hospital, said in a news release. "These results will encourage a change in practice across the country so that more women can benefit from the currently underutilized approach of administering estrogen-lowering agents before surgery."

The findings are scheduled to be presented June 7 at the American Society of Clinical Oncology annual meeting, in Chicago.

More information

For more on surgical options for breast cancer, visit the U.S. National Cancer Institute.



--Alan Mozes



SOURCE: American Society of Clinical Oncology meeting, May 20, 2010, news release.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted therapy prolongs life in patients with HER2-positive breast cancer
2. New Drugs, New Combinations Fight Breast Cancer
3. Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks
4. Carol Milgard Breast Center Awarded Highest Government Rating for Mammography Sites
5. Prolactin blocks oncogene associated with poor prognosis in breast cancer
6. Definitive study confirms chemo benefit in postmenopausal breast cancer
7. Adding Chemo to Tamoxifen Helps Some Breast Cancer Patients
8. Major New Study Finds Soyfoods Safe and Beneficial for Women With Breast Cancer
9. Bone Drugs May Beat Back Breast Cancer
10. California Breast Cancer Survivors and Advocates Call on State to Nix Screening Cuts
11. Alcohol consumption may increase breast cancer recurrence risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The American Board ... become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon ... beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the Law ... organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our ... a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
(Date:9/12/2017)...  Consumer reviews on the independent review site Consumer Affairs ... company for hearing aids, ranking it higher than Miracle Ear ... ... For Hearing Aids ... online store that provides high performance, state-of-the-art, German-engineered hearing aids directly ...
Breaking Medicine Technology: